Bionomics (BST:B1N0) - Stock Price, News & Analysis

B1N0 Stock Overview

A clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers.

About the company

B1N0 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Risk Analysis

Does not have a meaningful market cap (€5M)

Makes less than USD$1m in revenue ($0)

Shareholders have been substantially diluted in the past year

Has less than 1 year of cash runway

+ 3 more risks

Bionomics Limited Competitors

co.don

XTRA:CNW

€6.5m

bioXXmed

XTRA:T5O

€698.7k

Medigene

XTRA:MDG1

€31.0m

Heidelberg Pharma

XTRA:HPHA

€112.8m

Price History & Performance

Summary of all time highs, changes and price drops for Bionomics
Historical stock prices
Current Share Price	US$0.25
52 Week High	US$4.12
52 Week Low	US$0.24
Beta	-0.16
11 Month Change	-55.04%
3 Month Change	-58.02%
1 Year Change	-92.70%
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-98.03%

Recent updates

Shareholder Returns

	B1N0	DE Biotechs	DE Market
7D	-53.8%	0.2%	-1.0%
1Y	-92.7%	-9.9%	12.8%

Return vs Industry: B1N0 underperformed the German Biotechs industry which returned -9.9% over the past year.

Return vs Market: B1N0 underperformed the German Market which returned 12.8% over the past year.

Price Volatility

Is B1N0's price volatile compared to industry and market?
B1N0 volatility
B1N0 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.2%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.1%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: B1N0's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine B1N0's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1996	16	Spyros Papapetropoulos	www.bionomics.com.au

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company’s lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.

Bionomics Limited Fundamentals Summary

How do Bionomics's earnings and revenue compare to its market cap?
B1N0 fundamental statistics
Market cap	€4.39m
Earnings (TTM)	-€14.11m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.3x

P/E Ratio

Is B1N0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
B1N0 income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$15.49m
Earnings	-US$15.49m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.89
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did B1N0 perform over the long term?

See historical performance and comparison

Bionomics BST:B1N0 Stock Report